Comparing the current results to its competitors, Tempest Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.31 %, recorded in the same quarter.
Tempest Therapeutics Inc , slower than the average decrease reported by the company's competitors of -55.98 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -55.98 %
Tempest Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical and immuno-oncology sectors, which are characterized by rapid innovation and significant competition. Competitors include large and specialty pharmaceutical and biotechnology firms, academic research institutions, government agencies, and both public and private research organizations. These competitors are developing a range of cancer treatments such as chemotherapy drugs, small molecules, monoclonal antibodies, antibody-drug conjugates, bi-specific antibodies, cell therapies, oncolytic viruses, and vaccines.
For the company's products TPST-1495 and amezalpat, clinical development competitors include Ono, Adlai Nortye, Merck, Roche, Exelixis, and AstraZeneca. In the area of cell therapies, competitors developing CAR-T and other cellular therapies targeting diseases addressed by TPST-2003, TPST-3003, and TPST-4003 include Johnson & Johnson, Bristol Myers Squibb, Gilead Sciences, Arcellx, Legend Biotech, Allogene, Cellectis, and AstraZeneca. Additional competitors in this space include other biotechnology and pharmaceutical companies developing BCMA-targeting and dual-targeting cell therapies.
October 10, 2024
: Tempest Therapeutics, a biopharmaceutical company focused on innovative cancer therapies, has announced a significant partnership with Roche to advance their Amezalpat combination therapy into a pivotal Phase 3 clinical trial for the treatment of first-line hepatocellular carcinoma (HCC). This article outlines the implications of this collaboration, the details of the upcoming clinical study, and the potential impact of the Amezalpat therapy on treating HCC, a prevalent form of liver cancer.Hepatocellular carcinoma, accounting for roughly 75% of liver cancer cases globally, poses substantial treatment challenges due to its often late diagnosis and poor prognosis. Existing treatment options are limited, par...
August 15, 2024
Tempest Therapeutics Announces Success in End-of-Phase 2 Meeting with FDA for Innovative Cancer Therapy BRISBANE, Calif., Aug. 15, 2024 In a significant development for cancer therapeutics, Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company, has announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding amezalpat (TPST-1120). This drug is designed to be used in combination with atezolizumab and bevacizumab for the treatment of first-line unresectable or metastatic hepatocellular carcinoma (HCC).The successful discussions with the FDA mark an important milestone for Tempest Therapeutics, as they look forward to adva...
June 18, 2024
Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for a significant proportion of cancer-related deaths worldwide. The limited effectiveness of existing treatment options and the high mortality rates associated with HCC have sparked considerable interest in exploring novel therapeutic approaches. In this article, we report on the groundbreaking data presented by Tempest Pharmaceuticals, unveiling the findings of a global randomized combination study of Amezalpat (TPST-1120) as a first-line treatment for HCC.Unveiling the Data:Tempest Pharmaceuticals, a leading biopharmaceutical company focused on oncology and immune diseases, hosted a webcast conference call on Thursday, Jun...
June 7, 2024
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company devoted to advancing first-in-class targeted and immune-mediated therapies to combat cancer, has made significant strides with two key announcements that promise to impact the company’s future trajectory profoundly. Inducement Grant for Strategic GrowthOn June 7, 2024, Tempest Therapeutics disclosed that its Compensation Committee had approved a nonqualified stock option grant for one of its employees under the company’s 2023 Inducement Plan. This grant comprises options to purchase 14,000 shares of the company s common stock. Issued under Nasdaq Listing Rule 5635(c)(4), such inducement awards are considered vital tools to ...
April 9, 2024
Tempest Therapeutics TPST-1120 Shows Promise in Reducing Kidney Cancer Growth as a Monotherapy and in Combination with Chemotherapy and Immunotherapy, According to Preclinical Data Presented at AACR Annual Meeting Tempest Therapeutics, Inc. (Nasdaq: TPST), a pioneering biotechnology company specializing in the development of targeted and immune-mediated therapeutics to combat cancer, recently unveiled significant preclinical data at the esteemed American Association for Cancer Research (AACR) Annual Meeting in support of their investigational drug, TPST-1120. Collaborators at the renowned Beth Israel Deaconess Medical Center (BIDMC) at Harvard Medical presented compelling findings demonstrating the drug s ...
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.
Sources:
Tempest Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tempest Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
